Pharmacy Technician Pulse

Fierce Pharma Asia—AstraZeneca's KRAS bet; BeiGene's cancer deal; Coherus' PD-1 price

Fierce Pharma

NOVEMBER 30, 2023

we're highlighting two weeks' worth of biopharma news related to Asia. Because of the recent Thanksgiving holiday in the U.S., AstraZeneca in-licensed a KRAS G12D inhibitor from China's Usynova. BeiGene bought global rights to a CDK2 inhibitor in a deal worth up to $1.3 market at a 20% discount to Merck's Keytruda.

Fierce Pharma Asia—Astellas' brief IRA fight; Otsuka's psychedelic buy; Takeda's court loss

Fierce Pharma

SEPTEMBER 8, 2023

Three Japanese pharma companies lead our news stories from Asia this week. Astellas has abandoned its challenge against the Inflation Reduction Act. Astellas has abandoned its challenge against the Inflation Reduction Act. Otsuka bought a Canadian psychedelic biotech.

Bob Tribe, ISPE Asia-Pacific Regulatory Advisor, Retires

ISPE

FEBRUARY 13, 2023

In his role as ISPE’s Asia-Pacific Regulatory Advisor Bob was instrumental in helping ISPE establish a presence and increase membership in the Asia-Pacific region, and well as introducing regional health authorities to ISPE.

Documentation

Documentation FDA

Fierce Pharma Asia—China's reimbursement round; Sun's alopecia bet; GenScript's CDMO raise

Fierce Pharma

JANUARY 19, 2023

Fierce Pharma Asia—China's reimbursement round; Sun's alopecia bet; GenScript's CDMO raise aliu Thu, 01/19/2023 - 15:53

Asia-Pacific Regulatory & Industry Views on Drug Shortage Prevention

ISPE

MAY 22, 2023

The webinar was moderated by Vivien Santillan, Regional Director, Asia, Novatek International. Susan Mountain Regional Supply Chain Lead for South East Asia, Hong Kong & India Amgen Assuring quality suppliers versus cost was emphasized by Susan Mountain of Amgen. Global harmonization of processes (e.g.,

Communication

Communication FDA

Fierce Pharma Asia—Carvykti's massive myeloma win; BeiGene's PD-1 comeback

Fierce Pharma

APRIL 20, 2023

Fierce Pharma Asia—Carvykti's massive myeloma win; BeiGene's PD-1 comeback aliu Thu, 04/20/2023 - 15:00

Fierce Pharma Asia—Eisai's subQ Leqembi delay; Legend and J&J's supply deal with Novartis; China's Ozempic biosimilar

Fierce Pharma

APRIL 4, 2024

Fierce Pharma Asia—Eisai's subQ Leqembi delay; Legend and J&J's supply deal with Novartis; China's Ozempic biosimilar aliu Thu, 04/04/2024 - 16:14

Fierce Pharma Asia—Takeda's manufacturing expansion; Leqembi's sales prospects; GSK's PrEP generics

Fierce Pharma

MARCH 30, 2023

Fierce Pharma Asia—Takeda's manufacturing expansion; Leqembi's sales prospects; GSK's PrEP generics aliu Thu, 03/30/2023 - 16:18

Fierce Pharma Asia—Takeda's 'challenging' year; AZ's cancer buy; Astellas' menopause drug nod

Fierce Pharma

MAY 18, 2023

Fierce Pharma Asia—Takeda's 'challenging' year; AZ's cancer buy; Astellas' menopause drug nod aliu Thu, 05/18/2023 - 22:47

CPHI South East Asia visitor numbers expected to double as interest in drug supply chain security booms

Outsourcing Pharma

JULY 6, 2023

This yearâs CPHI South East Asia is expecting a surge in international partnering with organizers expecting a record attendance of 8,000 visitors including a significant number from overseas â doubling last yearâs figures.

Fierce Pharma Asia—Carvykti's EU filing; Thermo Fisher's Singapore expansion; Celltrion's Humira biosim nod

Fierce Pharma

MAY 26, 2023

Fierce Pharma Asia—Carvykti's EU filing; Thermo Fisher's Singapore expansion; Celltrion's Humira biosim nod aliu Fri, 05/26/2023 - 08:43

Fierce Pharma Asia—Eisai and Biogen's Leqembi progress; AZ and Daiichi's Enhertu data; Samsung Biologics' manufacturing deal

Fierce Pharma

JUNE 8, 2023

Fierce Pharma Asia—Eisai and Biogen's Leqembi progress; AZ and Daiichi's Enhertu data; Samsung Biologics' manufacturing deal zbecker Thu, 06/08/2023 - 19:34

Fierce Pharma Asia—BioNTech's ADC deal; Sanofi's potential consumer cut; Takeda's latest celiac play

Fierce Pharma

APRIL 6, 2023

Fierce Pharma Asia—BioNTech's ADC deal; Sanofi's potential consumer cut; Takeda's latest celiac play aliu Thu, 04/06/2023 - 15:39

Fierce Pharma Asia—Takeda's $4B psoriasis data; Biohaven's neurology bet; Pfizer and Astellas' Xtandi wins

Fierce Pharma

MARCH 23, 2023

Fierce Pharma Asia—Takeda's $4B psoriasis data; Biohaven's neurology bet; Pfizer and Astellas' Xtandi wins aliu Thu, 03/23/2023 - 18:29

Fierce Pharma Asia—Takeda's cancer deal; BeiGene's Brukinsa nod; Astellas' gene therapy reprieve

Fierce Pharma

JANUARY 26, 2023

Fierce Pharma Asia—Takeda's cancer deal; BeiGene's Brukinsa nod; Astellas' gene therapy reprieve aliu Thu, 01/26/2023 - 14:58

Fierce Pharma Asia—Eisai's lecanemab Alzheimer's debate; BeiGene's Imbruvica showdown; Shionogi's COVID drug nod

Fierce Pharma

DECEMBER 2, 2022

Fierce Pharma Asia—Eisai's lecanemab Alzheimer's debate; BeiGene's Imbruvica showdown; Shionogi's COVID drug nod. Fri, 12/02/2022 - 08:55.

Fierce Pharma Asia—Samsung's deal with Pfizer; Olympus' and Dr. Reddy's M&A moves; BeiGene's growth

Fierce Pharma

MARCH 2, 2023

Fierce Pharma Asia—Samsung's deal with Pfizer; Olympus' and Dr. Reddy's M&A moves; BeiGene's growth aliu Thu, 03/02/2023 - 15:58

Fierce Pharma Asia—BioNTech, GSK grow in Singapore; Astellas' stomach cancer win; Daiichi's mRNA vaccine readout

Fierce Pharma

NOVEMBER 18, 2022

Fierce Pharma Asia—BioNTech, GSK grow in Singapore; Astellas' stomach cancer win; Daiichi's mRNA vaccine readout. Fri, 11/18/2022 - 09:44.

Vaccines

Fierce Pharma Asia—J&J, Legend's CAR-T win; Sanofi's India job cuts; BeiGene, Novartis' PD-1 delay

Fierce Pharma

FEBRUARY 2, 2023

Fierce Pharma Asia—J&J, Legend's CAR-T win; Sanofi's India job cuts; BeiGene, Novartis' PD-1 delay aliu Thu, 02/02/2023 - 15:58

Fierce Pharma Asia—Eisai’s Alzheimer’s trial deaths; Moderna’s first M&A deal; GSK, WuXi's bispecific pact

Fierce Pharma

JANUARY 6, 2023

Fierce Pharma Asia—Eisai’s Alzheimer’s trial deaths; Moderna’s first M&A deal; GSK, WuXi's bispecific pact. Fri, 01/06/2023 - 10:36.

Idorsia sells off its Asia Pacific operations to raise funds

Pharmaceutical Technology

JULY 21, 2023

To reduce cash burn, the company has sold off its Asia Pacific operations, except in China, and looks to reduce R&D costs.

How did hiring in the Asia-Pacific pharma industry perform in Q2 2023

Pharmaceutical Technology

JULY 27, 2023

The Asia-Pacific pharma industry experienced a 4% drop in hiring activity in Q2 2023, led by Syngene International's 10% share, according to GlobalData

How did hiring in the Asia-Pacific pharma industry perform in Q2 2023

Pharmaceutical Technology

JULY 27, 2023

The Asia-Pacific pharma industry experienced a 4% drop in hiring activity in Q2 2023, led by Syngene International's 10% share, according to GlobalData

Fierce Pharma Asia—Daiichi's leukemia delay, Enhertu gains; Glenmark's settlement

Fierce Pharma

APRIL 27, 2023

Fierce Pharma Asia—Daiichi's leukemia delay, Enhertu gains; Glenmark's settlement aliu Thu, 04/27/2023 - 22:47

Fierce Pharma Asia—Roche, Eisai's HER2 deals; Takeda's layoffs in the US

Fierce Pharma

MAY 11, 2023

Fierce Pharma Asia—Roche, Eisai's HER2 deals; Takeda's layoffs in the US aliu Thu, 05/11/2023 - 15:14

Women in Pharma® Editorial: Women in Pharma® Expands in Asia

ISPE

OCTOBER 26, 2022

Women in Pharma® Editorial: Women in Pharma® Expands in Asia. Women in Pharma® Editorial: Women in Pharma® Expands in Asia. Growth in Asia. After more than two years of online conferences, meetings, and webinars, Asia is slowly opening its borders once again and seeing a growth in Women in Pharma® initiatives. Santillan.

CPhI South East Asia rescheduled for 2021

Pharma Mirror

AUGUST 11, 2020

CPhI South East Asia – organised by Informa Markets – has been rescheduled to May 18-20, 2021 to give the ASEAN pharma community more time to recover and to mitigate any global disruptions caused by COVID-19. The post CPhI South East Asia rescheduled for 2021 appeared first on Pharma Mirror Magazine.

Fierce Pharma Asia—Eisai's Leqembi hurdle; AZ's cancer deal; and Mitsubishi's royalty win

Fierce Pharma

FEBRUARY 23, 2023

Fierce Pharma Asia—Eisai's Leqembi hurdle; AZ's cancer deal; and Mitsubishi's royalty win aliu Thu, 02/23/2023 - 15:26

Fierce Pharma Asia—Takeda's gene therapy pivot and pay-for-delay lawsuit; Astellas' write-offs

Fierce Pharma

APRIL 13, 2023

Fierce Pharma Asia—Takeda's gene therapy pivot and pay-for-delay lawsuit; Astellas' write-offs aliu Thu, 04/13/2023 - 16:07

Fierce Pharma Asia—Astellas' new CEO; Eisai's Alzheimer’s launch; Mitsubishi's Medicago closure

Fierce Pharma

FEBRUARY 10, 2023

Fierce Pharma Asia—Astellas' new CEO; Eisai's Alzheimer’s launch; Mitsubishi's Medicago closure aliu Fri, 02/10/2023 - 08:10

Fierce Pharma Asia—Sun's price-fixing settlement; Eisai's coverage win; AstraZeneca's India layoffs

Fierce Pharma

MARCH 16, 2023

Fierce Pharma Asia—Sun's price-fixing settlement; Eisai's coverage win; AstraZeneca's India layoffs aliu Thu, 03/16/2023 - 14:52

Fierce Pharma Asia—Leqembi's priority review; Enhertu's broad trial win; Cipla's FDA censure

Fierce Pharma

MARCH 9, 2023

Fierce Pharma Asia—Leqembi's priority review; Enhertu's broad trial win; Cipla's FDA censure aliu Thu, 03/09/2023 - 15:27

FDA

Fierce Pharma Asia—Takeda's trial win, Biogen's pipeline pivot and Astellas' Super Bowl debut

Fierce Pharma

FEBRUARY 16, 2023

Fierce Pharma Asia—Takeda's trial win, Biogen's pipeline pivot and Astellas' Super Bowl debut aliu Thu, 02/16/2023 - 15:08

Asia-Pacific is seeing a hiring boom for robotics roles in pharma

Pharmaceutical Technology

JULY 19, 2022

Asia-Pacific was the fastest growing region for robotics hiring among pharmaceutical industry companies in the three months ending May. The number of roles in Asia-Pacific made up 2.6% The post Asia-Pacific is seeing a hiring boom for robotics roles in pharma appeared first on Pharmaceutical Technology.

Fierce Pharma Asia—Eisai's Leqembi nod; 2 Astellas licensing deals; Samsung's ADC plan

Fierce Pharma

JANUARY 12, 2023

Fierce Pharma Asia—Eisai's Leqembi nod; 2 Astellas licensing deals; Samsung's ADC plan. Fri, 01/13/2023 - 00:30.

Fierce Pharma Asia—Astellas' eye drug buy; J&J's latest CAR-T deal; Sun's clinical hold

Fierce Pharma

MAY 4, 2023

Fierce Pharma Asia—Astellas' eye drug buy; J&J's latest CAR-T deal; Sun's clinical hold aliu Thu, 05/04/2023 - 17:10

Fierce Pharma Asia—MEI and Kyowa Kirin’s PI3K woes; Takeda’s dengue nod, Daiichii Sankyo’s Enhertu positivity

Fierce Pharma

DECEMBER 9, 2022

Fierce Pharma Asia—MEI and Kyowa Kirin’s PI3K woes; Takeda’s dengue nod, Daiichii Sankyo’s Enhertu positivity. esagonowsky. Fri, 12/09/2022 - 10:43.

Who’s hiring who? Hiring activity in the Asia-Pacific pharma industry increased by 2% in Q1 2023

Pharmaceutical Technology

JUNE 9, 2023

The Asia-Pacific pharma industry experienced a 2% rise in new job postings in Q1 2023 compared with the previous quarter, with the highest share accounted for by Biocon with 8,387 job postings, according to GlobalData’s analysis of pharma company job postings. Buy the report here.

Fierce Pharma Asia—German CEOs visit China; Sanofi, Insilico's $1.2B pact; Sumitomo's job cuts

Fierce Pharma

NOVEMBER 10, 2022

Fierce Pharma Asia—German CEOs visit China; Sanofi, Insilico's $1.2B pact; Sumitomo's job cuts. Thu, 11/10/2022 - 16:53.

Fierce Pharma Asia—Geopolitical tensions in biotech; Carvykti, Enhertu win new labels; Fujifilm's $1.2B expansion

Fierce Pharma

APRIL 11, 2024

Geopolitical tensions are casting uncertainties over cross-border biotech deals. Geopolitical tensions are casting uncertainties over cross-border biotech deals. Johnson & Johnson and Legend Biotech's Carvykti, plus AstraZeneca and Daiichi Sankyo's Enhertu, secured new FDA approvals.

Labelling

Labelling FDA

3rd World ADC Asia

pharmaphorum

FEBRUARY 8, 2024

Optimising Physiochemical, Potency & Impurity Analytical Methods to Ensure Regulatory Compliance

Fierce Pharma Asia—BIO-WuXi break-off; Takeda's site closure; FDA's concern over Carvykti

Fierce Pharma

MARCH 15, 2024

WuXi AppTec left the Biotechnology Industry Organization amid increasing pressure on the trade group stemming from a draft U.S. bill targeting certain Chinese biotechs. WuXi AppTec left BIO amid alleged biosecurity concerns and as U.S. lawmakers target certain Chinese biotechs.

FDA

Launch of world-first expert resource to foster best practice osteoporosis care in the Asia Pacific

Pharma Mirror

OCTOBER 22, 2021

New Delhi, India, More than 50 per cent of the world’s hip fractures are expected to occur in the Asia Pacific by the year 2050. The post Launch of world-first expert resource to foster best practice osteoporosis care in the Asia Pacific appeared first on Pharma Mirror Magazine.

Biden administration announces new partnership with 50 countries to stifle future pandemics

STAT

APRIL 16, 2024

government officials will offer support in the countries, most of them located in Africa and Asia , to develop better testing, surveillance, communication, and preparedness for such outbreaks in those countries. Read the rest…

Communication

Fierce Pharma Asia—AstraZeneca's KRAS bet; BeiGene's cancer deal; Coherus' PD-1 price

Fierce Pharma Asia—Astellas' brief IRA fight; Otsuka's psychedelic buy; Takeda's court loss

Trending Sources

Bob Tribe, ISPE Asia-Pacific Regulatory Advisor, Retires

Fierce Pharma Asia—China's reimbursement round; Sun's alopecia bet; GenScript's CDMO raise

Asia-Pacific Regulatory & Industry Views on Drug Shortage Prevention

Fierce Pharma Asia—Carvykti's massive myeloma win; BeiGene's PD-1 comeback

Fierce Pharma Asia—Eisai's subQ Leqembi delay; Legend and J&J's supply deal with Novartis; China's Ozempic biosimilar

Fierce Pharma Asia—Takeda's manufacturing expansion; Leqembi's sales prospects; GSK's PrEP generics

Fierce Pharma Asia—Takeda's 'challenging' year; AZ's cancer buy; Astellas' menopause drug nod

CPHI South East Asia visitor numbers expected to double as interest in drug supply chain security booms

Fierce Pharma Asia—Carvykti's EU filing; Thermo Fisher's Singapore expansion; Celltrion's Humira biosim nod

Fierce Pharma Asia—Eisai and Biogen's Leqembi progress; AZ and Daiichi's Enhertu data; Samsung Biologics' manufacturing deal

Fierce Pharma Asia—BioNTech's ADC deal; Sanofi's potential consumer cut; Takeda's latest celiac play

Fierce Pharma Asia—Takeda's $4B psoriasis data; Biohaven's neurology bet; Pfizer and Astellas' Xtandi wins

Fierce Pharma Asia—Takeda's cancer deal; BeiGene's Brukinsa nod; Astellas' gene therapy reprieve

Fierce Pharma Asia—Eisai's lecanemab Alzheimer's debate; BeiGene's Imbruvica showdown; Shionogi's COVID drug nod

Fierce Pharma Asia—Samsung's deal with Pfizer; Olympus' and Dr. Reddy's M&A moves; BeiGene's growth

Fierce Pharma Asia—BioNTech, GSK grow in Singapore; Astellas' stomach cancer win; Daiichi's mRNA vaccine readout

Fierce Pharma Asia—J&J, Legend's CAR-T win; Sanofi's India job cuts; BeiGene, Novartis' PD-1 delay

Fierce Pharma Asia—Eisai’s Alzheimer’s trial deaths; Moderna’s first M&A deal; GSK, WuXi's bispecific pact

Idorsia sells off its Asia Pacific operations to raise funds

How did hiring in the Asia-Pacific pharma industry perform in Q2 2023

How did hiring in the Asia-Pacific pharma industry perform in Q2 2023

Fierce Pharma Asia—Daiichi's leukemia delay, Enhertu gains; Glenmark's settlement

Fierce Pharma Asia—Roche, Eisai's HER2 deals; Takeda's layoffs in the US

Women in Pharma® Editorial: Women in Pharma® Expands in Asia

CPhI South East Asia rescheduled for 2021

Fierce Pharma Asia—Eisai's Leqembi hurdle; AZ's cancer deal; and Mitsubishi's royalty win

Fierce Pharma Asia—Takeda's gene therapy pivot and pay-for-delay lawsuit; Astellas' write-offs

Fierce Pharma Asia—Astellas' new CEO; Eisai's Alzheimer’s launch; Mitsubishi's Medicago closure

Fierce Pharma Asia—Sun's price-fixing settlement; Eisai's coverage win; AstraZeneca's India layoffs

Fierce Pharma Asia—Leqembi's priority review; Enhertu's broad trial win; Cipla's FDA censure

Fierce Pharma Asia—Takeda's trial win, Biogen's pipeline pivot and Astellas' Super Bowl debut

Asia-Pacific is seeing a hiring boom for robotics roles in pharma

Fierce Pharma Asia—Eisai's Leqembi nod; 2 Astellas licensing deals; Samsung's ADC plan

Fierce Pharma Asia—Astellas' eye drug buy; J&J's latest CAR-T deal; Sun's clinical hold

Fierce Pharma Asia—MEI and Kyowa Kirin’s PI3K woes; Takeda’s dengue nod, Daiichii Sankyo’s Enhertu positivity

Who’s hiring who? Hiring activity in the Asia-Pacific pharma industry increased by 2% in Q1 2023

Fierce Pharma Asia—German CEOs visit China; Sanofi, Insilico's $1.2B pact; Sumitomo's job cuts

Fierce Pharma Asia—Geopolitical tensions in biotech; Carvykti, Enhertu win new labels; Fujifilm's $1.2B expansion

3rd World ADC Asia

Fierce Pharma Asia—BIO-WuXi break-off; Takeda's site closure; FDA's concern over Carvykti

Launch of world-first expert resource to foster best practice osteoporosis care in the Asia Pacific

Biden administration announces new partnership with 50 countries to stifle future pandemics

Stay Connected